Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R. Chaib I, et al. Among authors: verlicchi a. J Natl Cancer Inst. 2017 Sep 1;109(9):djx014. doi: 10.1093/jnci/djx014. J Natl Cancer Inst. 2017. PMID: 28376152 Free PMC article.
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Among authors: verlicchi a. Sci Rep. 2015 Dec 7;5:17499. doi: 10.1038/srep17499. Sci Rep. 2015. PMID: 26639561 Free PMC article.
Cancer stem cells in small cell lung cancer.
Codony-Servat J, Verlicchi A, Rosell R. Codony-Servat J, et al. Among authors: verlicchi a. Transl Lung Cancer Res. 2016 Feb;5(1):16-25. doi: 10.3978/j.issn.2218-6751.2016.01.01. Transl Lung Cancer Res. 2016. PMID: 26958490 Free PMC article. Review.
HER3 as a Therapeutic Target in Cancer.
Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R. Karachaliou N, et al. Among authors: verlicchi a. BioDrugs. 2017 Feb;31(1):63-73. doi: 10.1007/s40259-016-0205-2. BioDrugs. 2017. PMID: 28000159 Review.
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M. Lazzari C, et al. Among authors: verlicchi a. Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 10.1080/17476348.2017.1326822. Epub 2017 May 15. Expert Rev Respir Med. 2017. PMID: 28467720 Review.
Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Among authors: verlicchi a. Sci Rep. 2023 Mar 3;13(1):3620. doi: 10.1038/s41598-023-30374-9. Sci Rep. 2023. PMID: 36869103 Free PMC article. No abstract available.
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C. Ulivi P, et al. Among authors: verlicchi a. Int J Mol Sci. 2014 Dec 31;16(1):747-57. doi: 10.3390/ijms16010747. Int J Mol Sci. 2014. PMID: 25561229 Free PMC article.
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A. Ulivi P, et al. Among authors: verlicchi a. Clin Lung Cancer. 2016 Sep;17(5):384-390. doi: 10.1016/j.cllc.2015.11.004. Epub 2015 Dec 1. Clin Lung Cancer. 2016. PMID: 26712101
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Bronte G, Verlicchi A, De Matteis S, Rossi A, Affatato A, Sullo FG, Gianni C, Canale M, Burgio MA, Delmonte A, Milella M, Crinò L. Bronte G, et al. Among authors: verlicchi a. Front Immunol. 2021 May 27;12:672219. doi: 10.3389/fimmu.2021.672219. eCollection 2021. Front Immunol. 2021. PMID: 34122429 Free PMC article.
34 results